2,501 research outputs found
Recommended from our members
Distinctive Mechanisms and Patterns of Exudative Versus Tractional Intraretinal Cystoid Spaces as Seen With Multimodal Imaging.
PurposeTo determine clear-cut distinctions between tractional and exudative intraretinal cystoid spaces subtypes.DesignRetrospective, multicenter, observational case series.MethodsA cohort of patients diagnosed with intraretinal cystoid spaces and imaged with optical coherence tomography (OCT), fluorescein angiography (FA), blue fundus autofluorescence (BFAF), en face OCT, and OCT angiography (OCT-A) was included in the study. All images were qualitatively and quantitatively evaluated.ResultsIn this study were included 72 eyes of 69 patients. Exudative intraretinal cystoid spaces (36/72 eyes, 50%) displayed a "petaloid" morphology as seen with en face OCT, FA, and BFAF. Tractional intraretinal cystoid spaces (24/72 eyes, 33.3%), displayed a radial "spoke-wheel" en face OCT pattern. There was no leakage with FA and BFAF did not reveal specific patterns. Eyes with full-thickness macular hole (FTMH, 12/72 eyes, 16.7%) displayed a "sunflower" en face OCT appearance. FTMH showed OCT, OCT-A, and BFAF features of both exudative and tractional cystoid spaces, but without any FA leakage. Inner nuclear layer (INL) thickness was significantly lower in tractional cystoid spaces (P < .001). There were a greater number of INL cystoid spaces in both the exudative and FTMH subgroups (PÂ = .001). The surface area of INL cystoid spaces was significantly lower in the tractional subgroup (P < .001). There was a significant reduction of the microvascular density in eyes with exudative vs tractional (PÂ = .002) and FTMH (P < .001) subgroups.ConclusionsExudative and tractional intraretinal cystoid spaces displayed characteristic multimodal imaging features and they may represent 2 different pathologic conditions with equally different clinical implications
A tip-tilt hardware-in-the-loop air-bearing test bed with physical emulation of the relative orbital dynamics
29th AAS/AIAA Space Flight Mechanics Meeting: Ka’anapali, Maui, Hawaii, U.S.A. Volume: Advances in the Astronautical Sciences (Vol. 168, pp. 3781–3799). Univelt Inc.A new hardware-in-the-loop (HIL) air bearing testbed that is capable of physically emulating the relative orbital dynamics is presented. Typically, air bearing testbeds consist of test vehicles operating on top of a planar and horizontally-leveled sur face. These test vehicles use air bearings to reduce the friction with the operating surface to negligible levels. The low friction, combined with the horizontally leveled surface, creates a low residual acceleration environment. These dynamics are representative of the environment that spacecraft experience during close proximity maneuvers. To extend the applicability of planar air bearing test beds to longer maneuvers or separations relative orbital dynamics need to be emulated. In this paper, using Hill-Clohessy-Wilshire dynamics, we emulated the relative orbital dynamics of a real spacecraft using a scaled Floating Spacecraft Simulator (FSS) on a dynamically inclined operating surface. The mathematical constructs of the tilt angles, screw height displacements and scaling parameters are developed via Euler’s rotation theorem, Buckingham’s Pi theorem and the similarity principle. The applicability of the new idea is demonstrated via a circumnavigation maneuver scenario of a spacecraft in a Low Earth Orbit (LEO). The simulation results show the viability and suitability of the new approach
Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis
BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities can reduce oedema and thereby improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO. OBJECTIVES: The 2014 update of this review found high-quality evidence of benefit with antiangiogenic therapy with anti-VEGF modalities, compared to laser photocoagulation, for the treatment of DMO.The objective of this updated review is to compare the effectiveness and safety of the different anti-VEGF drugs in preserving and improving vision and quality of life using network meta-analysis methods. SEARCH METHODS: We searched various electronic databases on 26 April 2017. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared any anti-angiogenic drug with an anti-VEGF mechanism of action versus another anti-VEGF drug, another treatment, sham or no treatment in people with DMO. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods for pair-wise meta-analysis and we augmented this evidence using network meta-analysis methods. We focused on the relative efficacy and safety of the three most commonly used drugs as interventions of direct interest for practice: aflibercept and ranibizumab, used on-label; and off-label bevacizumab.We collected data on three efficacy outcomes (gain of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters; mean change in best-corrected visual acuity (BCVA); mean change in central retinal thickness (CRT)), three safety outcomes (all severe systemic adverse events (SSAEs); all-cause death; arterial thromboembolic events) and quality of life.We used Stata 'network' meta-analysis package for all analyses. We investigated the risk of bias of mixed comparisons based on the variance contribution of each study, having assigned an overall risk of bias to each study. MAIN RESULTS: Twenty-four studies included 6007 participants with DMO and moderate vision loss, of which two studies randomised 265 eyes of 230 participants and one was a cross-over study on 56 participants (62 eyes) that was treated as a parallel-arm trial. Data were collected on drugs of direct interest from three studies on aflibercept (975 eyes), eight studies on bevacizumab (515 eyes), and 14 studies on ranibizumab (1518 eyes). As treatments of indirect interest or legacy treatment we included three studies on pegaptanib (541 eyes), five studies on ranibizumab plus prompt laser (557 eyes), one study on ranibizumab plus deferred laser (188 eyes), 13 studies on laser photocoagulation (936 eyes) and six studies on sham treatment (793 eyes).Aflibercept, bevacizumab and ranibizumab were all more effective than laser for improving vision by 3 or more lines after one year (high-certainty evidence). Approximately one in 10 people improve vision with laser, and about three in 10 people improve with anti-VEGF treatment: risk ratio (RR) versus laser 3.66 (95% confidence interval (CI) 2.79 to 4.79) for aflibercept; RR 2.47 (95% CI 1.81 to 3.37) for bevacizumab; RR 2.76 (95% CI 2.12 to 3.59) for ranibizumab. On average there was no change in visual acuity (VA) with laser after one year, compared with a gain of 1 or 2 lines with anti-VEGF treatment: laser versus aflibercept mean difference (MD) -0.20 (95% CI -0.22 to -0.17) logMAR; versus bevacizumab MD -0.12 (95% CI -0.15 to -0.09) logMAR; versus ranibizumab MD -0.12 (95% CI -0.14 to -0.10) logMAR. The certainty of the evidence was high for the comparison of aflibercept and ranibizumab with laser and moderate for bevacizumab comparison with laser due to inconsistency between the indirect and direct evidence.People receiving ranibizumab were less likely to gain 3 or more lines of VA at one year compared with aflibercept: RR 0.75 (95% CI 0.60 to 0.94), moderate-certainty evidence. For every 1000 people treated with aflibercept, 92 fewer would gain 3 or more lines of VA at one year if treated with ranibizumab (22 to 148 fewer). On average people receiving ranibizumab had worse VA at one year (MD 0.08 logMAR units, 95% CI 0.05 to 0.11), moderate-certainty evidence; and higher CRT (MD 39 µm, 95% CI 2 µm to 76 µm; low-certainty evidence). Ranibizumab and bevacizumab were comparable with respect to aflibercept and did not differ in terms of VA: RR of gain of 3 or more lines of VA at one year 1.11 (95% CI 0.87 to 1.43), moderate-certainty evidence, and difference in change in VA was 0.00 (95% CI -0.02 to 0.03) logMAR, moderate-certainty evidence. CRT reduction favoured ranibizumab by -29 µm (95% CI -58 µm to -1 µm, low-certainty evidence). There was no evidence of overall statistical inconsistency in our analyses.The previous version of this review found moderate-certainty evidence of good safety of antiangiogenic drugs versus control. This update used data at the longest available follow-up (one or two years) and found that aflibercept, ranibizumab and bevacizumab do not differ regarding systemic serious adverse events (SSAEs) (moderate- or high-certainty evidence). However, risk of bias was variable, loop inconsistency could be found and estimates were not precise enough on relative safety regarding less frequent events such as arterial thromboembolic events or death (low- or very low-certainty evidence).Two-year data were available and reported in only four RCTs in this review. Most industry-sponsored studies were open-label after one year. One large publicly-funded study compared the three drugs at two years and found no difference. AUTHORS' CONCLUSIONS: Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. There is moderate-certainty evidence that aflibercept confers some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms. Relative effects among anti-VEGF drugs at two years are less well known, since most studies were short term. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated and under-monitored.We found no signals of differences in overall safety between the three antiangiogenic drugs that are currently available to treat DMO, but our estimates are imprecise for cardiovascular events and death
duloxetine induced pseudolymphoma with features of lymphocytic infiltration of jessner kanof
n/
Ascorbic acid (Redoxon®) supplementation modulates gene expression in peripheral blood mononuclear cells specifically upon an inflammatory stimulus. A pilot study
Study of a New Trigger on Multiplicity and Primary Interaction Vertex using the ALICE Silicon Pixel Detector
New trigger inputs for the ALICE Central Trigger Processor (CTP) are proposed. They are based on the use of Fast Multiplicity (FM) output signals generated by the ALICE Silicon Pixel Detector (SPD). These can be used for a multiplicity based centrality trigger and for a fast on-line computation of the primary vertex. A simple algorithm for primary vertex location at the trigger level is proposed. The precision that can be achieved with this method on centrality selection and primary vertex location, is discussed for interactions with different pseudo-rapidity density level. The feasibility of background rejection is also considered
LNCaP Prostate Cancer Growth In Vivo: Oncostatic Effects of Melatonin as Compared to Hypoxia and Reoxygenation
Gravitational radiation from precessing accretion disks in gamma-ray bursts
We study the precession of accretion disks in the context of gamma-ray burst
inner engines. Our aim is to quantitatively estimate the characteristics of
gravitational waves produced by the precession of the transient accretion disk
in gamma-ray bursts. We evaluate the possible periods of disk precession caused
by the Lense-Thirring effect using an accretion disk model that allows for
neutrino cooling. Assuming jet ejection perpendicular to the disk plane and a
typical intrinsic time-dependence for the burst, we find gamma-ray light curves
that have a temporal microstructure similar to that observed in some reported
events. The parameters obtained for the precession are then used to evaluate
the production of gravitational waves. We find that the precession of accretion
disks of outer radius smaller than cm and accretion rates above 1 solar
mass per second could be detected by Advanced LIGO if they occur at distances
of less than 100 Mpc. We conclude that the precession of a neutrino-cooled
accretion disk in long gamma-ray bursts can be probed by gravitational wave
astronomy. Precession of the disks in short gamma-ray events is undetectable
with the current technology.Comment: 5 pages, 5 figures, accepted for publication in A&
- …